Brii Bio joins the NIH graveyard alongside GSK, Lilly after flopping antibody study in hospitalized Covid-19 patients
Just a day after GlaxoSmithKline and Vir Biotechnology’s Covid-19 antibody fell flat in an NIH-sponsored trial for hospitalized patients, researchers have ejected another therapy from the study. Is this the death knell for monoclonal antibodies for those patients? An antibody cocktail from Brii Biosciences failed to show a trend toward